Skip to main content
. 2024 May 31;12(5):e008689. doi: 10.1136/jitc-2023-008689

Table 2.

Response, disease control rate, and durability of response

NIVO+RELA
(n=50)
Investigator assessed BICR assessed
Objective response rate, n (%) 25 (50) 24 (48)
95% CI 35.5 to 64.5 33.7 to 62.6
Best overall response, n (%)
Complete response 5 (10) 8 (16)
Partial response 20 (40) 16 (32)
Stable disease 12 (24) 11 (22)
Progressive disease 13 (26) 14 (28)
Unable to determine 0 1 (2)
Disease control rate,* n (%) 35 (70) 32 (64)
95% CI 55.4 to 82.1 49.2 to 77.1
Median time to response (range),† months 2.8 (1.3–33.1) 2.7 (1.4–19.4)
Median duration of response (95% CI),† months 42.7 (27.7 to not estimable) Not reached (21.9 to not estimable)

*CR+PR+SD (for at least 12 weeks); 95% CI based on the Clopper-Pearson method.

†Evaluated in patients who had an objective response.

BICR, blinded independent central review; CR, complete response; NIVO, nivolumab; PR, partial response; RELA, relatlimab; SD, stable disease.